Clinical trial · Interventional
Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual due to COVID-19 and lower accrual than expected.
Summary
Brief summary (as posted)
The investigators aim to optimize the radiation treatment of early stage lung cancer patients. Therefore, detailed understanding is needed of the type of toxicity and the location of these toxicities for patients who receive high fraction doses. These have not been measured in these patients before, therefore our primary research question is: is it possible to measure changes in cardiac condition after radiotherapy, with respect to cardiac arrhythmias, fibrosis, hemodynamic function change and pericarditis?
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Stage I | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Lung Cancer Stage II | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Lung Metastases | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiac condition measurements | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- A
- description
- Radiotherapy; SBRT Additional cardiac diagnostics
- interventionNames
- Diagnostic Test: Cardiac condition measurements
Primary outcomes (5)
- measure
- Percentage of patients with a change in cardiac condition
- timeFrame
- 1 year
- description
- Percentage of patients with at least 5% change in cardiac arrhythmia (outcome 2) and/or at least 5% change in fibrosis (outcome 3) and/or at least 5% change in hemodynamic function (outcome 4) and/or development of pericarditis post-treatment (outcome 5)
- measure
- Percentage of change in cardiac arrhythmia
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Receive SBRT treatment for stage 1A-2B NSCLC or for a solitary lung metastasis of a solid tumour * Closest distance between edge of tumor and heart \< 3 cm Exclusion Criteria: * Pacemaker/ICD * Renal function below GFR \<30 ml/min/1.7m2
References
Publications (0)
Data not yet available